Continue to Submission Form

In just a few easy steps, submit your innovation.

CSL logos

Welcome to CSL’s Open Innovation Submission Portal

CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives. Innovation has been in CSL's DNA for more than a century. CSL has the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. Our strengths enable us to accurately identify, successfully develop, and dependably deliver innovations for patients.

At CSL we believe that for innovation to be fast tracked, we need to partner with the brightest minds in the sector. We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and we collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients' unmet needs around the globe.

If you have an idea related to new products, new technologies or new advancements relating to CSL's areas of interest, please feel free to share it via the Submission Form. All submissions will be screened by yet2 and if successful, will be shared with CSL. Initial submissions should not include any confidential information.

Focus Areas

CSL is seeking new ideas in the these focus areas. Please click on the links below to find out more about these areas and our current interests.

CSL's mission is to discover, develop and deliver our innovative therapies that improve the patients' quality of life while maintaining the highest product safety standards and continually improving manufacturing effectiveness. We know that partnerships can accelerate innovation and delivery of new unique technologies, assets, and equipment, to address patients’ unmet needs around the globe. Below you will find our current interest areas where we seek innovative ideas that can improve our processes, equipment, and analytical capabilities within our three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapies.



Click on the buttons below to learn more:


  • Cell & Gene Therapy
    • In vivo kill switch or suicide switch: technology that allows the in vivo removal of gene-modified cells
    • Innovations that enable modulation of transgene expression in vivo: technologies that may be able to tune the expression of a transgene delivered by lentiviral gene therapy
    • Novel methods to select gene modified hematopoietic stem cells (HSCs): technologies that allow for in vivo selection of gene–modified cells
    • Novel gene therapy targets aligned with CSL's Therapeutic Areas: novel gene therapy or gene editing targets, through any mode of delivery, aligned with CSL's therapeutic areas of interest
    • Non-viral in vivo delivery strategies for ribonucleoproteins (RNPs): lipid nanoparticle (LNP) or polymer-based
  • Oral delivery technologies
    • Novel technologies that enable oral delivery of biologic therapeutics including monoclonal antibodies and large recombinant protein therapeutics